文献速递心外重症与机械循环支持

基于倾向性评分的耐久性离心左心室辅助装置长期随访分析:EUROMACS研究

Propensity score-based analysis of long-term follow-up in patients supported with durable centrifugal left ventricular assist devices: the EUROMACS analysis.
PubMed 文献 · Eur J Cardiothorac Surg · 2021-01-01

该研究基于EUROMACS注册数据,对2016年1月至2020年9月期间植入HeartWare HVAD或HeartMate3的成人患者进行倾向性评分匹配回顾性分析,每组361例。两组2年生存率相似,但HVAD组设备故障、神经功能障碍和颅内出血风险显著更高。

要点

  • 倾向性匹配后HVAD与HM3的2年生存率无显著差异。
  • HVAD组设备故障风险显著高于HM3组(SHR 2.44)。
  • HVAD组神经功能障碍和颅内出血风险更高。

核心结论

  • 倾向性匹配分析显示两组中期生存相似,但HVAD组设备故障、神经功能障碍和颅内出血风险显著更高。

研究设计与样本

  • 回顾性分析EUROMACS注册中2016年1月1日至2020年9月1日植入HVAD或HM3的成人患者,经1:1倾向性评分匹配后每组361例。

主要发现

  • 2年生存率HVAD组61% 95%CI(56-67%)与HM3组68% 95%CI(63-73%)相似,分层风险比1.13 95%CI(0.83-1.54),P=0.435。
  • 主要不良事件合并意外再入院累积发生率两组相似,SHR 1.0(0.84-1.21),P=0.96。
  • HVAD组设备故障风险更高,SHR 2.44(1.45-3.71),P<0.001。
  • HVAD组神经功能障碍风险更高,SHR 1.29(1.02-1.61),P=0.032。
  • HVAD组颅内出血风险更高,SHR 1.76(1.13-2.70),P=0.012。

临床怎么用

  • 在选择耐久性离心左心室辅助装置时,需权衡HVAD较高的设备故障、神经功能障碍和颅内出血风险与HM3的相似生存获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The HeartWare HVAD (HW) and the HeartMate3 (HM3) are presently the most commonly used continuous-flow left ventricular assist devices worldwide. We compared the outcomes of patients supported with either of these 2 devices based on data from the EUROMACS (European Registry for Patients with Mechanical Circulatory Support). METHODS: A retrospective analysis of the survival and complications profile in propensity score-matched adult patients enrolled in the EUROMACS between 01 January 2016 and 01 September 2020 and supported with either an HW or HM3. Matching included demographic parameters, severity of cardiogenic shock and risk-modifying end-organ parameters that impact long-term survival. Survival on device and major postoperative adverse events were analysed. RESULTS: Following 1:1 propensity score matching, each group consisted of 361 patients. Patients were well balanced (<0.1 standardized mean difference). The median follow-up was similar in both groups [396 (interquartile range (IQR) 112-771) days for HW and 376 (IQR 100-816) days for HM3]. The 2-year survival was similar in both groups [HW: 61% 95% confidence interval (CI) (56-67%) vs HM3: 68% 95% CI (63-73%) (stratified hazard ratio for mortality: 1.13 95% CI (0.83-1.54), P = 0.435].The cumulative incidence for combined major adverse events and unexpected readmissions was similar in both groups [subdistribution hazard ratio (SHR) 1.0 (0.84-1.21), P = 0.96]. Patients in the HW group demonstrated a higher risk of device malfunction [SHR 2.44 (1.45-3.71), P < 0.001], neurological dysfunction [SHR 1.29 (1.02-1.61), P = 0.032] and intracranial bleeding [SHR 1.76 (1.13-2.70), P = 0.012]. CONCLUSIONS: Mid-term survival in both groups was similar in a propensity-matched analysis. The risk of device malfunction, neurological dysfunction and intracranial bleeding was significantly higher in HW patients.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Potapov EV, Nersesian G, Lewin D, et al. Propensity score-based analysis of long-term follow-up in patients supported with durable centrifugal left ventricular assist devices: the EUROMACS analysis. Eur J Cardiothorac Surg. 2021. PMID: 33871594. doi:10.1093/ejcts/ezab144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。